問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林振源

Recruiting

List

66Cases

2021-10-01 - 2027-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting13Sites

Terminated3Sites

2025-03-31 - 2028-01-31

Phase I

Active
A Phase 1B, Multicenter, Open-Label Study of the Safety and Efficacy of CHS-114 in Combination With Toripalimab With or Without Other Treatments in Participants With Advanced or Metastatic Solid Tumors

  • Condition/Disease

    Metastatic Solid Tumor、 Advanced Solid Tumor

  • Test Drug

    靜脈點滴注射劑 靜脈點滴注射劑

Participate Sites
10Sites

Recruiting10Sites

2022-01-05 - 2026-01-06

Phase I/II

Completed
A Phase 1/2 Dose Escalation/Expansion Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

  • Condition/Disease

    Mesothelioma

  • Test Drug

    靜脈輸注液

Participate Sites
4Sites

Recruiting4Sites

2025-02-07 - 2032-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2022-06-16 - 2026-06-30

Phase I/II

Active
A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer naïve to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06A.

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma (ESCC)

  • Test Drug

    Keytruda injection RMK-4830MK-4280A Lenvima capsule R Lenvima capsule R Intaxel Injection R Irinotel Intravenous Infusion Concentrate

Participate Sites
7Sites

Recruiting7Sites

2019-10-01 - 2046-12-31

Phase III

Active
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    Pembrolizumab

Participate Sites
12Sites

Recruiting12Sites

2021-07-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-08-17 - 2023-12-12

Phase I/II

Completed
A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors

  • Condition/Disease

    Advanced/Metastatic Solid Tumors

  • Test Drug

    V937;吉舒達®/Keytruda®

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

2022-12-15 - 2027-12-31

Phase I/II

Active
A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma

  • Test Drug

    Lenvima capsule 4 mgR/ Lenvima capsule 4 mgR KeytrudaR/ KeytrudaR Lenvima capsule 10 mgR/ Lenvima capsule 10 mgRMK-4830 IntaxelR Cancer Treatment Intravenous Infusion Concentrate/ IrinotelR

Participate Sites
7Sites

Recruiting7Sites

2021-10-01 - 2027-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

1 2 3 4 5 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB